Home
Mission
The mission of the Center for Neurodegenerative Disease Research (CNDR) is to promote and conduct multidisciplinary clinical and basic research to increase the understanding of the causes and mechanisms leading to brain dysfunction and degeneration in neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy body dementia (LBD), Frontotemporal degeneration (FTD), Amyotrophic lateral sclerosis (ALS), Primary lateral sclerosis (PLS), Motor neuron disease (MND), and related disorders that occur increasingly with advancing age. Implicit in the mission of the CNDR are two overarching goals: 1.) Find better ways to cure and treat these disorders, 2. Provide training to the next generation of scientists.
“My vision for CNDR is to create a world with effective interventions to prevent and cure aging-related neurodegenerative diseases.” – Eddie Lee, MD, PhD, Director of CNDR
John Q. Trojanowski, MD, PhD | 1946 - 2022
In loving memory of John Q. Trojanowski, MD, PhD
Latest Research
-
White matter hyperintensities and the structural connectome: a network perspective on clinical heterogeneity
Wednesday, September 23, 2026
White matter hyperintensities (WMH) are common radiological findings with diverse clinical outcomes, including absence of clinical symptom, cognitive decline and dementia. One potential explanation for these differences is that WMH could differentially disrupt specific white matter tracts and lead to alterations in structural brain networks. We included participants from the UK Biobank who had available information on WMH volume and divided them into three groups: healthy controls (HC),...
-
Diagnosing Dementias: Many Names, Many Faces
Wednesday, September 23, 2026
No abstract
-
Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions
Tuesday, September 22, 2026
Duchenne muscular dystrophy (DMD) is an X-linked recessive dystrophinopathy characterized by progressive loss of muscle strength, respiratory insufficiency, cardiac dysfunction, and premature death. Despite a rapidly evolving therapeutic landscape that now includes multiple disease modifying treatments including exon skipping medications, microdystrophin gene therapy, and givinostat, high dose glucocorticoids (GCs) initiated at a young age remain central to the standard of care for DMD....